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Hyperglycemia in the surgical population is a recognized risk factor for postoperative complications; however, there is little lit-
erature to date regarding the management of hyperglycemia in the perioperative period. Here, we detail the strategies that our
institutions have employed to identify and treat hyperglycemia in patients with diabetes who present for surgery. Our approach
focuses on the recognition of hyperglycemia and metabolic abnormalities, control of glucose levels via insulin infusion when
needed, monitoring for hypoglycemia and a comprehensive multidisciplinary approach that provides standardized recommenda-
tions for patients at all points in care as they transition from the preoperative clinic into the operating room, and then into the
hospital.
1.Background
Studies have demonstrated that hyperglycemia occurs in a
signiﬁcant percentage of hospitalized patients; seventy per-
cent of patients with diabetes admitted with acute coronary
syndrome and 80% of cardiac surgery patients in the periop-
erative period may develop hyperglycemia [1]. Over the past
few decades, there has been mounting evidence that hyper-
glycemia in hospitalized patients leads directly to adverse
consequences. In particular, the literature indicates a role
for glycemic control in surgical patients, where postoperative
hyperglycemia is associated with an increased risk of infec-
tion, renal and pulmonary complications, and also mortality
[2–7]. More recent studies have addressed the eﬀects of
hyperglycemia perioperatively and conﬁrmed similar asso-
ciations [8–11]. One study demonstrated that for every
20mg/dL increase in the mean intraoperative glucose, the
risk of an adverse outcome increased by more than 30% [8].
While the majority of intervention trials for glycemic
control have taken place in critical care settings and in
the cardiac surgery population (and have been extrapolated
to other clinical situations), some data is now emerging
for general hospital wards and in patients undergoing
noncardiac surgery [12, 13]. However, there are few clin-
ical trials that have speciﬁcally studied the intraoperative
period. In one intervention trial in patients undergoing
cardiac surgery, attempting to achieve intraoperative tight
glycemic control (<100mg/dL) did not show improvement
in outcomes when compared to good glycemic control
(<200mg/dL) [14]. However, in another study by Subrama-
nian et al. [12], involving 236 patients undergoing vascular
surgery, subjects randomized preoperatively to a continuous
intravenous insulin infusion protocol (goal glucose range
100–150mg/dL) versus an intermittent intravenous bolus
protocol (treatment if >150mg/dL) had a lower rate of
perioperative myocardial infarction. This trial, though, was
underpowered. While strong evidence to support speciﬁc
insulin strategies in the operating room are lacking, practi-
tioners have recognized that intraoperative glycemic control
assists in achieving early postoperative glycemic control.
Glucose control on the hospital ﬂoor can take several days to
accomplish even when patient-tailored subcutaneous insulin
programs are utilized [13, 15, 16], as there are many factors
that can eﬀect glycemic control in hospitalized [17]a n d
critically ill patients [18].2 Anesthesiology Research and Practice
Table 1: Current recommendations for glycemic control in critically ill patients.
Organization Year Patient population Treatment threshold (mg/dL) Target glucose
Surviving sepsis campaign 2008 ICU patients 180 <150
American heart association 2009
Patients with
Acutecoronary
syndrome
180 <140
European society of
cardiology 2009 Patients after major
noncardiac surgery 180 140–180
Institute of healthcare
improvement 2009 ICU patients 180 <180
American diabetes
association 2011 ICU patients 180 140–180
American college of
physicians 2011
ICU
patients/hospitalized
patients
180 140–180
Based on available data, both of our institutions have
independently developed protocols to achieve rapid and safe
glycemic control via intravenous insulin in patients present-
ing for surgery. This therapy serves as a bridge to subcuta-
neous insulin to be continued during the hospital stay. Here,
we describe our experience creating and implementing these
protocols. The discussion below relates to glucose control in
patients with diabetes to be admitted to the hospital after
surgery. The topic of ambulatory surgery will not be ad-
dressed.
2. Layingthe Groundworkand
DesigningaProtocol
B e c a u s et h ep e r i o p e r a t i v et i m ep e r i o di n v o l v e sc a r eb y
multiple and diﬀerent physician groups, a multidisciplinary
team approach is key to the creation of a successful proto-
col. Depending on institutional practice, this may include
representatives from endocrinology, anesthesiology, surgery,
nursing, preoperative clinic, pharmacy, and information
technology(IT).Everytransitionpointforthepatientshould
be addressed, from the preoperative assessment clinic with
standardized recommendations for antihyperglycemic med-
ications before surgery, to transition to in-hospital postoper-
ative care as well as discharge preparation and education. It
is important that a standardized protocol for the treatment
of hypoglycemia be included whenever a hyperglycemia
protocol is instituted.
Preoperative control of glucose makes intuitive sense.
However,theidealrangeanddurationofglucosecontrolpri-
or to elective surgery has not been determined. No prospec-
tive study has been conducted to date to demonstrate that
preoperative glucose control improves perioperative out-
comes. A recent retrospective study involving more than
55,000 patients failed to demonstrate an association between
preoperative HbA1c and postoperative infection rate [11].
Furthermore, recent trials in nonoperative clinical situations
have failed to conclusively demonstrate that tight glucose
control as measured by HbA1c leads to signiﬁcantly better
cardiovascular outcomes [19]. It is because of this data that
the main focus has remained on achieving glucose control in
the hospital and upon discharge.
Due to its quick action and short half life, intravenous
(IV) insulin is the preferred choice for rapid correction
o fh y p e r g l y c e m i a .W h i l ep r o v i d e r sm a yb em o r ef a m i l i a r
with ordering subcutaneous regular insulin or rapid-acting
insulin analogs, it will take several hours for these insulins
to have their peak eﬀect and to be metabolized, which both
limits the frequency at which the medication can be redosed
and increases the amount of time the patient may require
monitoring(e.g.,thedurationofactionofsubcutaneousreg-
ular insulin is 6–10 hours). Furthermore, many factors can
aﬀect insulin absorption in the perioperative period and in
critically ill patients [7]. The result is an increased potential
for overlapping dose eﬀects, administration timing errors,
andunexpectedhypoglycemia.Thus,itisnowrecommended
that insulin be administered intravenously in the periopera-
tive period and for critically ill patients. Many institutions
with critical care units already have protocols for glycemic
control using intravenous insulin infusions, and these can
often be adapted for use in the operating room. If this is
not available, evidence-based insulin infusion protocols have
been published [20–27]. Protocols that incorporate the
current glucose value, the previous glucose values, and the
rate of the infusion are preferred [28, 29]. However, because
recommended goal glucose ranges have changed over time,
careful attention must be paid to the protocol target range.
Recent trials and meta-analyses have failed to show a ben-
eﬁt in attempting to achieve normoglycemia (e.g., 80–
110mg/dL) in diverse groups of critically ill patients and in
the operating room [14, 30–33], and, based on available data
and concerns about hypoglycemia, a more moderate goal
now seems prudent. The American Association of Clinical
Endocrinologists and the American Diabetes Association
recommend a glucose target of 140–180mg/dL in critically
illpatients[34].Manyotherorganizationshavemadesimilar
recommendations (Table 1)[ 35–39].
It is important that a plan be in place to treat hyper-
glycemia after the patient leaves the operating room (OR).
There is often confusion on the part of the providers who
assume that if a patient is started on an insulin infusion thatAnesthesiology Research and Practice 3
they must be admitted to the hospital or even the intensive
care unit in order to continue the infusion after surgery.
Instead the infusion should be viewed as a temporary inter-
vention to rapidly achieve metabolic control. Patients who
would normally be transferred to the ﬂoor after a procedure
should be assessed for transition to an appropriate hospital
regimen, such as basal-bolus insulin [34]. There are several
decision points in the perioperative time (arrival in the pre-
operative area, transfer to the OR, and transfering out the
postanesthesiacareunit)whenthepatients’therapywillneed
to be adjusted. Working to streamline and standardize these
decision points will limit delays and an unnecessary increase
in hospital resources and staﬀ time.
Other practical issues of the protocol will need to be
addressed including the availability of glucometers and pre-
made IV insulin bags. IT support can assist in creating stan-
dardized order sets for those institutions with computerized
orders.
3. Hypoglycemia
Hypoglycemia and the fear of hypoglycemia remain a major
barrier in the care of hospitalized patients. In prospective
studies, the incidence of signiﬁcant hypoglycemia is reported
to be up to six times higher in intensive glucose control
groups.Recentdatahasdemonstratedarelationshipbetween
hypoglycemia, morbidity, and mortality [40–44], though
whetherthehypoglycemiaiscausal,orasignofcriticalillness
has yet to be established [43, 45]. Physicians have a height-
ened and appropriate concern for patients who are sedated
as they will be unable to report symptoms, and the signs of
hypoglycemia may be masked. For patient safety, a standard
treatment algorithm for hypoglycemia must be included
as part of the glycemic protocol. Patients on intravenous
insulin infusions in the OR should have a glucose checked at
a minimum every sixty minutes, and more often as clinically
indicated. Monitoring methods can include the use of point-
of-care glucose meters or blood samples such as venous
blood gases during the procedure. One of the drawbacks of
glucose meter use is the variance between meter readings
and laboratory sample (allowed to be up to 20% by FDA
regulations). The FDA is currently reviewing these limits,
and revised regulations may be forthcoming. Many patient
factors are known to aﬀect the accuracy of the reading,
including pH,oxygenationstatus,andanemiaamongothers,
andthishasbeenshowntobeaparticularissueincriticallyill
patients [46, 47]. Additionally, when a glucose value is in the
hypoglycemic range, the accuracy is further decreased [47–
49].Caregiversusingthesedevicesneedtobeeducatedabout
their limitations and a value that is not consistent with the
clinical picture needs to be veriﬁed by a central laboratory
method. This issue is another reason not to target a glucose
value in the normoglycemic range but only treat if glucose is
more than 180mg/dL [39].
4.SurgicalCancellations
Currently no evidence-basedguidelines exist regarding when
to cancel a surgical procedure due to hyperglycemia. Given
the multitude ofpatient factorsinvolved as wellasthe variety
of surgical procedures and procedure urgency, it is unlikely
that recommendations based on outcomes will be forthcom-
ing. Providers need to weigh several issues when considering
this question. First of all, the urgency of surgery should
be considered. Secondly, hyperglycemia could represent an
unstable metabolic state, such as diabetic ketoacidosis, which
should be rapidly assessed in the preoperative area. Elective
surgery in unstable metabolic state is not recommended.
Furthermore,thechronicglycemicstateofthepatientshould
be considered. In our experience, most patients who present
for elective surgery with a glucose >300mg/dL have had
s i m i l a rv a l u e sd o c u m e n t e da sa no u t p a t i e n ta n da r ear e p -
resentation of chronically poor control, as opposed to a new
illness. In this situation, there are opportunities for providers
to identify and address the problem prior to the patient
arriving in the preoperative area. Another consideration is
thatthehyperglycemiamaybecausedbytheillnessforwhich
the patient presented for surgery (for example, osteomy-
elitis), which would not be expected to improve until the pa-
tient undergoes surgery. Providers need, therefore, to assess
the patient for stability, the need for the procedure, the risks
of the procedure, and the ability of the patient to achieve
glucose control if the surgery is postponed. We have used a
cutoﬀ of 300mg/dL (Boston Medical Center) as a trigger in
the preoperative area for evaluation for ketoacidosis either
via urine ketone dipstick or whole blood chemistry. At Yale
New-Haven Hospital, no cutoﬀ value to trigger evaluation
for ketoacidosis has been set. It has been left to the discretion
of the physician. However, it is recommended to postpone
nonurgent/emergent surgery if the glucose is >400mg/dL.
At Boston Medical Center, it is recommend to postpone
nonurgent procedures if the glucose is >500mg/dL, or at the
discretion of the physician at lower levels based on the risks
and urgency of the procedure.
5. Trainingand EducationalStrategies
The multidisciplinary nature of a perioperative protocol ne-
cessitates education over the course of time and in different
formats. At Boston Medical Center, this included surgical
and anesthesiology grand rounds to review data and rec-
ommendations and later a joint conference regarding the
practicalimplementationoftheprotocol.Therewerenursing
in-servicesaswellastrainingintheuseofglucosemetersand
point-of-caretestingwithketostix.NurseswithoutpriorICU
experience also needed training in insulin infusion adminis-
tration. At all steps, the physician groups were given updates
at conferences and via emails. We also developed an educa-
tional video that was available for viewing on the hospital
intranet.Theendocrinologyteamwastrainedintheprotocol
to provide support when issues arose. In order to assess the
safety of our protocol and to identify unforeseen issues, a
three-month pilot of the protocol was performed in one OR
area prior to it being used hospital wide. The leadership
group focused on the eﬃcacy at achieving glycemic control
and the incidence of hypoglycemia, as well as any needed
adjustments to nursing orders before deciding to expand4 Anesthesiology Research and Practice
Table 2: Challenges to creating and implementing a perioperative glycemic control protocol.
Challenges faced Solutions employed
Consensus of a need for action by key leaders in representative
departments and formation of Task force for perioperative
glycemic control
MD leaders in endocrinology and anesthesiology provided
education and interdepartmental outreach (e.g. conferences,
consultation) on risks of hyperglycemia and reviewed
hospital-speciﬁc patient outcomes as well as national data and
guidelines
Buy-in by providers at other levels of care who are in supportive
roles (e.g. nursing, pharmacy, laboratory) and hospital
administrators
Task force members met with hospital leaders to explain rationale
for intervention and demonstrate leadership endorsement
Designing a practical and eﬀective protocol suited to institutional
needs and capabilities
Task force conducted a multidisciplinary assessment of hospital
expertise and practice pattern including nursing and
anesthesiologist skill in the use of intravenous insulin. Protocols
were developed and piloted and further reﬁned prior to
institution-wide adoption
Obtaining resources required for program success, including
point-of-care glucose meters in preoperative, intraoperative, and
postoperative care areas
Representative of the task force worked directly with hospital
administrators for funding required for infrastructure and
equipment
Staﬀ training, including nursing, anesthesia, and endocrine staﬀ
regarding the protocol as well as speciﬁc skills in infusion therapy
and glucose meters
Nurse educators, pharmacists, and endocrinologists performed
education for support staﬀ in the perioperative area. Provider
education by each department and leadership group
Ensuring uniformity and ease of daily protocol use
Consistent elements were put in place: computerized order sets,
written protocols available in the perioperative areas and 24/7
pager access to a designated physician for support
Protocol maintenance and improvement
Scheduled reviews of eﬃcacy and safety with members from
representative departments, easily identiﬁable point person who
can be contacted with questions, concerns, and suggestions
Table 3: Comparisons between Boston Medical Center and Yale New Haven Protocols.
Boston medical center Yale new haven
Protocol leadership Endocrinology, anesthesiology,
nursing, pharmacy, and surgery
Endocrinology, intensivist,
anesthesiology, nursing, pharmacy,
surgery, and administrators
Target intraoperative glucose range 120–180 mg/dL 120–180mg/dL
Threshold for treatment of perioperative
hyperglycemia >180mg/dL >200mg/dL (pre-op)
>180mg/dl (intra- and post-op)
Threshold for evaluation of metabolic stability
preoperatively >300mg/dL At the discretion of the practitioner
Recommendation for cancellation of nonurgent
surgery∗ >500mg/dL >400mg/dL
∗See text for details. Surgery could also be cancelled at the discretion of the provider at a diﬀerent glucose level based on surgical urgency and procedure risk.
the program. Pilot results have been previously published
[50]. At Yale New Haven hospital, similar education was
employed, and an initial protocol was tried in the cardiotho-
racic ICU and then introduced to the perioperative services.
We are in the process of analyzing the data for our in-
hospitalpopulation.Table 2 summarizesthemainchallenges
that arose during the creation and implementation of these
protocols and how they were addressed.
6.ProgramDescriptions
There is currently a lack of evidence to guide providers
regarding the details of perioperative glycemic management.
We provide this information to report our experience and
inform the literature, not as a formula we wish to recom-
mend as the ideal or only way to approach the issue. Below,
we describe the patient ﬂow that occurs at each of our in-
stitutions for an example patient. A comparison of the two
programs is provided in Table 3.
BostonMedicalCenter:thepatientisseeninthepreoper-
ative careclinic the weekprior tosurgery.The endocrinology
and preoperative clinic have created a standard guideline to
adjust medications prior to surgery (Figures 1 and 2). All
patients undergoing surgery automatically have an order for
perioperative glycemic control in our computerized system
cuing the nurse to start the protocol. Upon arrival, thenurse
in the preoperative area will check a glucose level on all
patients with diabetes. Patients with a glucose level ofAnesthesiology Research and Practice 5
Oral Medications
e r u d e c o r P r e t f A e r u d e c o r P o t r o i r P n o i t a c i d e M
(i) Short-acting sulfonylureas:
Do not take the morning of procedure (a) Glipizide (Glucotrol)
(b) Glyburide (DiaBeta, Glynase,
(ii) Long-acting sulfonylureas: Do not take the evening prior to or the
morning of procedure Resume when eating
Resume when eating
Resume when eating
Resume when eating
Resume when eating
(a) Glimepiride (Amaryl)
(b) Glipizide XL (Glucotrol XL)
(iii) Biguanides: Do not take the morning of procedure
Do not take the day prior to procedure if
receiving contrast dye
Resume when eating. After contrast dye wait
48 hours and repeat creatinine prior to
restarting.
(a) Metformin (Glucophage)
(b) Metformin ER (Glucophage XL)
(iv) Thiazolidinediones:
Do not take the morning of procedure (a) Pioglitazone (Actos)
(b) Rosiglitazone (Avandia)
(v) Alpha-Glucosidase Inhibitors:
Do not take the morning of procedure (a) Acarbose (Precose)
(b) Miglitol (Glyset)
(vi) DPP-4 Inhibitors:
Do not take the morning of procedure
(a) Sitagliptan (Januvia)
(vii) Meglitinides:
(a) Nateglinide (Starlix)
(b) Repaglinide (Prandin)
Note: For combination medications, follow the guideline for the component medication that must be held for the longest time.
Micronase)
Resume when eating
Do not take the morning of procedure
Figure 1: Boston Medical Center Guidelines for Pre-procedure Outpatient Management of Antihyperglycemic Medications for Procedures
that Require “NPO” Status.
e r u d e c o r P r e t f A e r u d e c o r P o t r o i r P n o i t a c i d e M
Injectable Medications
e r u d e c o r p f o g n i n r o m e h t e k a t t o n o D ) a t t e y B ( e d i t a n e x E
Symlin (Pramlintide) Do not take the morning of procedure
Insulins
Glargine (Lantus) Take usual dose the night before or the
morning of procedure Resume usual schedule after procedure
Detemir (Levemir) Take usual dose the night before or the
morning of procedure Resume usual schedule after procedure
NPH (Humulin N, Novolin N) Take 1/2 of usual dose the morning of
procedure
Resume usual schedule when eating, 1/2
dose while NPO
Humalog mix 70/30, 75/25, Humulin 70/30,
50/50 Novolin 70/30 (all mixed insulins) Do not take the morning of procedure
Regular insulin (Humulin R, Novolin R) Do not take the morning of procedure
Lispro (Humalog), Aspart (Novolog),
Glulisine (Apidra) Do not take the morning of procedure
Subcutaneous Insulin infusion pumps Requires tailored recommendations. In general, most patients may continue their usual
basal rate and correction doses, and resume meal-time boluses when eating again
Resume when eating
Resume when eating
Resume when eating
Resume when eating
Resume usual schedule when eating
Figure 2: Boston Medical Center Guidelines for Pre-procedure Outpatient Management of Antihyperglycemic Medications Prior to
Procedures that Require “NPO” Status.6 Anesthesiology Research and Practice
ORAL 
HYPOGLYCEMICS
STOP evening 
before the 
procedure
Take short-acting insulin
as usual before dinner
night before surgery
LONG OR INTERMEDIATE
INSULIN 
(NIGHT BEFORE SURGERY)
DECREASE long/intermediate- 
acting insulin by 50%
(AM OF SURGERY)
administer only if blood glucose
>120 mg/dL
INSULIN PUMP
DECREASE basal rate 
by 20% at midnight
before surgery
LONG OR INTERMEDIATE
INSULIN 
(MORNING OF SURGERY)
HOLD short-acting 
AM insulin
DECREASE 
long/intermediate 
acting insulin by 20%
night before surgery
Figure 3: Recommendations for adjusting antiglycemic medications (oral hypoglycemic, long- and short-acting insulin and insulin pump
infusion rates) preoperatively from Yale New Haven Hospital (see text for details).
≤180mg/dL proceed to surgery. Patients with a glucose level
of 181–300mg/dL are started on an IV insulin infusion by
the nurse prior to the proceeding of the operating room.
A 5% dextrose solution is also initiated to decrease the risk
of hypoglycemia. The goal glucose range on our infusion
protocol is 120–180mg/dL. The anesthesiologist is made
aware of the treatment in the preoperative area. The infusion
isincludedaspartofthepresurgicalWHOchecklisttoassure
all staﬀ are aware of the therapy, and the anesthesiologist
continues insulin titration according to the protocol in the
operating room. On arrival in the postanesthesia care unit,
the endocrine fellow is paged. The fellow provides recom-
mendations for a subcutaneous insulin program while in
the hospital. Patients with a glucose level >300mg/dL prior
to surgery have a metabolic evaluation for ketones or for
acidosis prior to starting the infusion and proceeding to
the operating room. As mentioned above, we recommend
postponing nonurgent procedures when the glucose is
>500mg/dL or at the discretion of the provider. For patients
with type 1 diabetes or patients on an insulin pump, the
endocrinology fellow is paged prior to surgery. It should be
noted that it took one year for our multidisciplinary team
to create the protocol, ensure the necessary equipment, and
perform the needed education prior to the three-month trial
pilot. After this, adjustments were made to the protocol, the
education was expanded, and it took nine months before the
protocol was used hospital wide.
Yale-New Haven Hospital: the protocol was developed
by the multidisciplinary perioperative team, which includes
anesthesiologists, endocrinologists, intensivists, nurses, and
administrators. Patients are seen in the preoperative anesthe-
sia clinic from a day to a few weeks prior to surgery. They are
advised to adjust their antihyperglycemic medications based
on the following guideline (Figure 3). Typically, the resident
physician or the nurse who evaluates the patient gives these
instructions. Patients who are on oral antihyperglycemic
medications are advised to discontinue their medications
the night before surgery. No oral hypoglycemic medications
are administered or advised on the morning of surgery.
Medications are reinstituted after the patient has resumed
a normal diet. For patients who are taking short or long
acting insulins adjustment of the insulin should take into
account the timing of their insulin regimen. Patients who
take both evening and morning doses of insulin should take
their usual dose of evening short-acting insulin, but reduce
their intermediate/long-acting insulin dose by 20% the night
before surgery. However the morning of surgery they should
omit their morning short acting insulin and reduce the
intermediate/long-acting dose by 50% (and take this only
if the fasting glucose is more than 120mg/dL). If patients
are using a premixed insulin they are instructed to reduce
their evening dose prior to surgery by 20% and hold insulin
completely morning of the procedure.
Patients with type 1 diabetes need some basal insulin at
all times. Short/rapid acting insulin alone will not suﬃce to
control blood glucose. Patients are instructed to take and
reducetheireveningintermediate/longactinginsulinby20%
the night before surgery. Those who use AM intermedi-
ate/long acting insulin are instructed to take 50% of their
usual dose (as long as fasting blood glucose is equal to or
more than 120mg/dL). For patients on insulin pumps, the
dosage should be reduced by 20% at midnight before sur-
gery. All patients with diabetes have their glucose checked
prior to elective surgery, and insulin therapy is started
based on written protocols. Urgent metabolic derangements
are assessed if dictated by clinical situation. In contrastAnesthesiology Research and Practice 7
to the protocol at Boston Medical Center, at Yale New-
Haven Hospital, IV insulin is not started in the preoperative
area. Based on a protocol, subcutaneous aspart insulin is
administered if the glucose is >200mg/dL. If the glucose
is >400mg/dL, the anesthesiologist is informed. Elective
surgery is discouraged if an acute rise in glucose levels to
>400mg/dL is noted or at the discretion of the provider.
The endocrine fellow is consulted if there are any concerns.
Glucose levels are measured intraoperatively if the patient
has diabetes or has been administered any insulin preopera-
tively. Intraoperatively insulin is administered intravenously,
and glucose is monitored hourly if an insulin infusion is
started (for blood glucose >180mg/dL) or if the patient is on
insulin pump. The goal is to maintain the glucose between
120–180mg/dL intraoperatively. Once the patient arrives in
the postanesthesia care unit, the insulin infusion is either
continued or transitioned a to basal-bolus program based on
the ﬁnal disposition of the patient. If the patient is on insulin
infusion, potassium is also monitored closely. Hypoglycemia
treatment is clearly addressed in the glycemic protocol and if
any untoward events or side eﬀects of insulin are noted, the
endocrinology fellow is consulted immediately.
7. Conclusion andFutureDirections
With the increasing prevalence of diabetes, practitioners will
continue to face the challenge of managing hyperglycemia
in patients during all aspects of the hospital stay. We note
that especially during the perioperative time where several
physician specialties are involved and many care transitions
will occur, it is critical that a multidisciplinary team be
utilized in addressing this issue. Variation in institutional
resources, staﬀ, and existing hospital practice will mean that
there is no “one size ﬁts all” approach. Many unanswered
questions remain as well as future research opportunities to
determine optimal intraoperative glucose targets, when to
postpone surgery, and speciﬁc populations who may show
greater or less beneﬁt from insulin therapy. Here, we provide
our experience and await more data to further reﬁne our
practice.
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